Hyperion Therapeutics Announces Initiation of THRIVE Study, a Long-Term Registry of Patients With Urea Cycle Disorders

Published: Oct 31, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has begun enrolling patients in its THRIVE study, a long term registry of patients with urea cycle disorders (UCDs) which will capture clinical outcomes and comparative effectiveness data.

Help employers find you! Check out all the jobs and post your resume.

Back to news